Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Talquetamab is a first-in-class GPRC5DxCD3 bispecific antibody approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM), and this multicenter retrospective analysis of 114 RRMM patients treated between October 2023 and January 2025 demonstrated significant efficacy in a heavily pretreated population with median 6 prior therapies. All patients were triple-class refractory, 79% were penta-refractory, and 65% had received prior BCMA-targeted therapy. The overall response rate was 73%, including complete response in 26% and very good partial response in 26%, with six-month progression-free and overall survival rates of 56 and 86% respectively and median progression-free survival of 10 months. Common adverse events included cytokine release syndrome (CRS; 54% with grade ≥2 in 7.3%), infections (27%), and immune effector cell-associated neurotoxicity syndrome (9.8%). The 3-month cumulative infection incidence of 14% for both bacterial and viral infections, where 59% were viral and 41% bacterial, grade ≥3 infections occurred in 18%, and intravenous immunoglobulin was used in 61% of patients. Significant weight loss was observed, with a mean 8.8% decrease at 6 months. This real-world analysis confirms talquetamab's efficacy in heavily pretreated RRMM while highlighting notable toxicities, including progressive weight loss and infections, which require rigorous monitoring and proactive supportive care.

Authors

Institutions

Publication Details

Journal
Blood Cancer Journal
Published
2025-11-07
DOI
https://doi.org/10.1038/s41408-025-01386-7
Citations
3
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
5.31
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Mansi R. Shah, Rajshekhar Chakraborty, Sharmilan Thanendrarajan, Aishee Bag et al.
3 citations
Blood Cancer Journal
Multiple Myeloma Research and Treatments
5.31
article

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Mansi R. Shah, Rajshekhar Chakraborty, Sharmilan Thanendrarajan, Aishee Bag, Anikó Szabó, Suzanne Lentzsch, Anita D’Souza, Simon Zhen, Samer Al Hadidi, Carolina Schinke, Meera Mohan, Binod Dhakal, Bhavesh Mohan Lal, Yetunde Ogunsesan, Maurizio Zangari, Frits van Rhee, Evanka Annyapu, Divaya Bhutani
article en
3 citations

Abstract

Talquetamab is a first-in-class GPRC5DxCD3 bispecific antibody approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM), and this multicenter retrospective analysis of 114 RRMM patients treated between October 2023 and January 2025 demonstrated significant efficacy in a heavily pretreated population with median 6 prior therapies. All patients were triple-class refractory, 79% were penta-refractory, and 65% had received prior BCMA-targeted therapy. The overall response rate was 73%, including complete response in 26% and very good partial response in 26%, with six-month progression-free and overall survival rates of 56 and 86% respectively and median progression-free survival of 10 months. Common adverse events included cytokine release syndrome (CRS; 54% with grade ≥2 in 7.3%), infections (27%), and immune effector cell-associated neurotoxicity syndrome (9.8%). The 3-month cumulative infection incidence of 14% for both bacterial and viral infections, where 59% were viral and 41% bacterial, grade ≥3 infections occurred in 18%, and intravenous immunoglobulin was used in 61% of patients. Significant weight loss was observed, with a mean 8.8% decrease at 6 months. This real-world analysis confirms talquetamab's efficacy in heavily pretreated RRMM while highlighting notable toxicities, including progressive weight loss and infections, which require rigorous monitoring and proactive supportive care.

Blood Cancer JournalVol. 15(1)
Rutgers, The State University of New Jersey (US), Medical College of Wisconsin (US), Columbia University Irving Medical Center (US), Johnson University (US), Southwestern Medical Center (US), Amyloidosis Foundation (US), Southwestern Medical Center (US), Herbert Irving Comprehensive Cancer Center, Columbia University (US), University of Arkansas for Medical Sciences (US), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 4%
Multiple Myeloma Research and Treatments
5.31
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.